Substantial or significant (used interchangeably) changes are a key element in lifecycle management of medical devices or device parts of (single) integral products.
In the European market, substantial changes affect:
→ Medical devices as defined in the Medical Device Regulation 2017/745 (MDR), Article 2 (1) – their leading regulatory framework is the MDR
→ Medical device parts of (single) integral products, as defined within the 2nd subparagraph of Article 1(8) / Article 1(9) of the MDR, such as single dose pre-filled syringes, pens and injectors – their leading regulatory framework is the Medicinal Products Directive 2001/83/EC (MPD); however the requirements outlined in MDR, Article 117 amend the MPD.
Depending on whether the product affected by the substantial change is a medical device or a device part of a (single) integral product, the requirements are different according to the respective leading regulation / directive and applicable guidelines. However, what they have in common is the need to determine if the change foreseen is a substantial change, as this has implications on the product’s regulatory situation.
Medical Device Regulation
outlines need for evaluation, documentation, data storage and notified body interaction
(e.g. per section 2.4 of Annex IX)
outlines need for a new (updated) EU certificate / declaration of conformity / opinion from a notified body aspart of the variation/extension application
In order to evaluate whether a change on a medical device oron a device part is significant or not, the focus aspect is to consider the influence on the device’s safety and performance.
The respective applicable regulation and guidance document statethe following:
Medical Device Regulation
“...where such changes could affect the safety and performance of thedevice or the conditions prescribed for use of the device. “ (persection 4.10 of Annex IX)
“Changes to the device componentare considered substantial if the changes affect the performance and safety characteristics of the device.”
Status as per June 2020, there is no guidance document / guideline present that provides more input onsignificant changes in the context of the MDR. However, in order to gain further clarity and granularity when assessing if a change is or is not considered significant, the decision trees outlined in MDCG 2020-3 (Guidance on significant changes regarding the transitional provision under Article 120 of the MDR with regard to devices covered by certificates according to MDD or AIMDD) are a valuable resource. Indeed, the main focus of the guidance is the effect of significant change on the transitional provisions under Article 120, but the considerations on safety and performance related influences are well reflected within the decision trees and are also applicable for the lifecycle related significant changes. Thus, being proactive, adapting and integrating these considerations / decision trees in your change management system will ensure your timely MDR readiness.
Would you like to know more about what this means for your business or what to do about it? Then don’t hesitate to reach out.
It is Child’s Safety Week from June 7 – June 13 2021 and we would like to raise awareness for this very important topic as well. This year’s slogan of the event “Share because you care” is why we would like to share our knowledge with you.
In our last article, we discussed the confusing situation regarding remote audits and the strategies that manufacturers can follow in order to qualify for this type of inspection under the MDR. In this article we focus on analysing Notified Bodies’ experience while conducting remote audits under the MDD and giving you practical advice for successfully going through it and try to devise the future of remote audits.